What I Saw When I Went to joinmochi.com
Short answer
Mochi Health’s compounded tirzepatide is advertised “as low as $90 a month,” but that is the medication alone at the lowest dose. Mochi also requires a membership: $79 a month, or less per month if you prepay 3, 6, or 12 months. The real month-to-month floor is about $169, and the medication price goes up as your dose increases. Prices verified on joinmochi.com in October 2026. For comparison, SkinnyVIP charges $695 for three months ($232/mo) or $350 for one month at any dose, with no membership.
I’m a physician. I run SkinnyVIP. And I still couldn’t figure out what Mochi Health’s compounded tirzepatide actually costs after five minutes on their website.
That’s not because Mochi is hiding anything illegal. It’s because their pricing page is built the way most subscription telehealth pricing pages are built: with a marketing-friendly starting number on the front, and the actual number a specific patient will pay tucked behind an intake flow. If a physician who does this for a living has to work for it, a prospective patient trying to comparison-shop between three or four providers is going to work for it too.
This is what I ran into when I went to joinmochi.com on September 8, 2026, trying to answer one simple question: what will Mochi Health charge me each month for compounded tirzepatide?
Wall 1: “As Low As $90”
The first number on Mochi’s tirzepatide card is “As low as $90” per month for the medication itself. That’s the anchor. It’s the number Mochi wants you to walk away with, and it’s the number that shows up in searches for “mochi tirzepatide price.”
Except “as low as” means “this is the floor.” It doesn’t mean “this is what you’ll pay.” The page doesn’t publish a numeric range and doesn’t publish a high-end price. It just tells you the lowest configuration — presumably the lowest dose, on the longest plan, in a state where the promotional pricing is available — reaches $90.
Mochi’s own site adds the caveats that spell that out:
- “Terms vary by state.”
- “Promotional pricing not available in all states.”
- “Medication availability and pricing vary by state.”
Translation: the $90 you just anchored on may or may not apply to you, at your dose, in your state, on your plan length. And the site doesn’t tell you what the actual price for your situation is. To find that out, you have to sign up.
This isn’t unique to Mochi. The “as low as [floor price]” format is standard across compounded GLP-1 telehealth. It’s worth flagging because it’s the industry pattern, not because any one company invented it. See our 4-provider pricing comparison for how the same starting-price mechanic shows up across Henry Meds, Ro, and LillyDirect.
Wall 2: Membership Required (But How Much?)
The next thing I noticed on the tirzepatide card was a small line: a Mochi membership is required to access this medication.
Okay. What does the membership cost?
The tirzepatide card doesn’t say. You have to scroll to a different part of the homepage — or click into a separate flow — to find that the membership itself is $79 per month on the monthly plan (or $207, $354, or $588 prepaid for 3, 6, or 12 months), with an intro offer that varies by page — a free first month on the 1-month plan, or $39 for the first month.
That’s another separately-charged recurring line item on top of the medication cost. Mochi’s page also notes that medications and diagnostic services are not included in the membership subscription, so the membership is genuinely a separate charge, not a bundled price.
So now the actual math for a new Mochi patient in month one looks like:
- Medication: starts at $90 (may be higher depending on dose, state, and plan length — not published)
- Membership: $0–$39 (intro offer; varies by page)
- Month one total: at least $90–$129, potentially more
And in month two, the membership steps up:
- Medication: starts at $90 (still may be higher — not published)
- Membership: $79
- Month two and beyond total: at least $169, potentially more
That’s the floor a new Mochi tirzepatide patient can expect. What the ceiling is depends on their dose, their state, and their plan length — and the site doesn’t say.
Wall 3: The Membership Itself
Even setting aside the price uncertainty, the membership structure itself matters for how the ongoing relationship works.
A membership is a recurring monthly subscription. It renews every month whether or not a patient is actively taking medication. It requires an action — typically contacting support or navigating an account setting — to stop the recurring charge. Mochi’s page states that the membership can be cancelled, and it’s not accurate to say Mochi hides that. But cancellation is still an active step a patient has to take on Mochi’s timing, not something that happens automatically at the end of a purchased supply.
Whether that’s a problem depends on how a patient prefers to manage healthcare subscriptions. Some patients like the always-on access a membership provides. Others have been burned enough times by subscriptions they forgot to cancel that they specifically don’t want another one, especially for a medication they may or may not stay on long-term.
What Mochi Does Well
Everything above is about price transparency and subscription mechanics. On the clinical and platform side, credit where it’s due — Mochi has real strengths:
- Board-certified obesity-medicine physicians. Mochi’s clinical team is built around obesity medicine as a specialty, not general telehealth staffed to handle weight-loss as one of many service lines. For patients who want a clinician with that specific specialty background, this is a genuine differentiator.
- Insurance navigation. Mochi has invested in helping patients understand and pursue insurance coverage for GLP-1 medications — a genuinely useful service given how confusing weight-loss drug coverage can be, and one that not every compounded-focused telehealth platform offers.
- Brand strength and patient volume. Mochi has built a large, well-reviewed patient base and a recognizable brand in the weight-loss telehealth category. That scale and polish matters to a lot of patients evaluating who to trust with ongoing care.
None of that is in dispute. Mochi is a reasonable choice for many patients, especially those actively working an insurance angle or who want an obesity-medicine specialist. This post is about a specific question — how easy is it to know what you’ll pay before you sign up — not a critique of Mochi’s clinical model.
What SkinnyVIP Shows You on the Pricing Page
Here’s the answer to the same question — “what will I actually pay each month?” — on SkinnyVIP’s pricing page:
- 3-Month Plan: $695 total, any dose from 2.5 to 15 mg per week. About $232 per month effective.
- 1-Month Plan: $350 total, any dose from 2.5 to 15 mg per week.
- Membership fee: None.
- Subscription: None. Neither plan auto-renews.
- Price change when your dose changes: $0.
That’s the whole pricing model. Two numbers, no membership, no subscription running in the background between plans. When a plan ends, it ends — nothing renews unless the patient actively starts a new plan. Compounded medications are not FDA-approved products; SkinnyVIP’s compounded tirzepatide is prepared by licensed compounding pharmacies under physician supervision. Individual results vary. Not affiliated with Novo Nordisk (Ozempic®/Wegovy®) or Eli Lilly (Mounjaro®/Zepbound®).
Whether that’s better depends on what a patient values. On sticker price, Mochi’s $90 floor is lower than SkinnyVIP’s $232 effective — on paper. On knowable price, SkinnyVIP tells you the number up front and it stays the same regardless of dose or state. If a patient values knowing exactly what they’ll pay before they enroll, that’s a different value proposition than the lowest possible sticker.